Feed aggregator
EH INVESTOR NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages EHang Holdings Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action Filed by the Firm – EH
NEW YORK--(BUSINESS WIRE)---- $EH #EH--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of EHang Holdings Limited (NASDAQ: EH) between January 20, 2022 and November 6, 2023, both dates inclusive (the “Class Period”), of the important February 2, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased EHang securities during the Class Period you may be entitled to compensation without payment of any out of poc
RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of RayzeBio, Inc. (NasdaqGM: RYZB) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of RayzeBio will receive $62.50 in cash for each share of RayzeBio that they own. KSF is seeking to determine whether this consideration and the process that led to it are adeq
THESEUS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Theseus Pharmaceuticals, Inc. - THRX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Theseus Pharmaceuticals, Inc. (NasdaqGS: THRX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Theseus will receive between $3.90 and $4.05 in cash for each share of Theseus that they own. KSF is seeking to determine whether this consideration and the process that le
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Gracell Biotechnologies Inc. (NasdaqGS: GRCL) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Gracell will receive $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (
DASEKE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Daseke, Inc. - DSKE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Daseke, Inc. (NasdaqCM: DSKE) to TFI International Inc. Under the terms of the proposed transaction, shareholders of Daseke will receive $8.30 in cash for each common share of Daseke that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether th
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Karuna Therapeutics, Inc. (NasdaqGM: KRTX) to Bristol-Myers Squibb Company (NYSE: BMY). Under the terms of the proposed transaction, shareholders of Karuna will receive $330.00 in cash for each share of Karuna that they own. KSF is seeking to determine whether this consideration and the process that led to it
Boston Millennia Partners Intends to Vote Against Proposed Merger of SomaLogic With Standard BioTools
BOSTON--(BUSINESS WIRE)--Boston Millennia Partners (“Boston Millennia”), a significant shareholder of SomaLogic (the “Company”) (Nasdaq: SLGC) today announced that it intends to vote against the Company’s planned merger (the “Merger”) with Standard BioTools Inc. (Nasdaq: LAB).
DG NOTICE: ROSEN, A LEADING LAW FIRM, Encourages Dollar General Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – DG
NEW YORK--(BUSINESS WIRE)---- $DG #DG--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Dollar General Corporation (NYSE: DG) between May 28, 2020 and August 30, 2023, both dates inclusive (the “Class Period”), of the January 26, 2024 lead plaintiff deadline. SO WHAT: If you purchased Dollar General common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WH
CHPT NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages ChargePoint Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CHPT
NEW YORK--(BUSINESS WIRE)---- $CHPT #CHPT--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ChargePoint Holdings, Inc. (NYSE: CHPT) between June 1, 2023 and November 16, 2023, both dates inclusive (the “Class Period”), of the important January 29, 2024 lead plaintiff deadline. SO WHAT: If you purchased ChargePoint securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem
BCLI FINAL DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Brainstorm Cell Therapeutics Inc. Investors with Losses in Excess of $500K to Secure Counsel Before Important January 2 Deadline in Securities Class Action Filed by the Firm
NEW YORK--(BUSINESS WIRE)---- $BCLI #BCLI--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) between August 15, 2022 and September 27, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Brainstorm Cell securities during the Class Period you may be entitled to compensation without paym
BARCLAYS DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Barclays PLC Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action Commenced by the Firm – BCS, BCLYF
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Barclays PLC (NYSE: BCS) (OTC: BCLYF) between July 22, 2019 and October 12, 2023, both dates inclusive (the “Class Period”), of the important January 2, 2024 lead plaintiff deadline in the securities class action commenced by the Firm. SO WHAT: If you purchased Barclays securities during the Class Period you may be entitled to compensation without payment of any out of pock